In the context of clinical trials, the renoprotective effects of SGLT2 inhibitors were proven in large scaled clinical trials as DAPA-CKD [15], EMPA-KIDNEY [16], CREDENCE [33], EMPA-REG [25], while these trials focused on hard renal clinical outcomes with eGFR monitoring being tertiary or explanatory outcomes. This evidence concerns the gene SLC5A2 and chronic kidney disease.